At what enterprise value was STADA acquired in 2017?

During the acquisition of STADA by BAIN CAPITAL / CINVEN in 2017, the transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR.

What was the EV/EBITDA of STADA when it was acquired by BAIN CAPITAL / CINVEN?

The estimated EV/EBITDA multiple for STADA is in the range of 10x - 18x.

When was STADA acquired by BAIN CAPITAL / CINVEN?

STADA was acquired by BAIN CAPITAL / CINVEN in 2017.

What was the revenue of STADA at the time of the deal?

The revenue of STADA at the time of the deal is estimated to be in the range of 1b - 3b EUR.

What was the EBITDA of STADA during the acquisition?

STADA's EBITDA is estimated to be in the range of 250M - 500M EUR.

How is the data for the STADA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the STADA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.stada.com/blog/posts/2017/april/to-the-shareholders-of-stada-arzneimittel-ag-stada-supports-voluntary-public-tender-offer-by-bain-capital-and-cinven#:~:text=The%20offer%20estimates%20STADA's%20equity,we%20have%20jointly%20signed%20today.

← DATABASE

Home Database Healthcare & PharmaSTADA

04/2017

STADA acquired by BAIN CAPITAL & CINVEN

GERMANY Life Sciences / Pharma & Biotech / Generics / Labs EV 3b - 100b EUR

Context

The Executive Board and Supervisory Board of STADA agreed to support a voluntary public tender offer from Bain Capital and Cinven. The offer of EUR66.00 per share (including dividend) values the company at an Enterprise Value of approximately EUR5.318 billion. This price represents a premium of roughly 49% over the unaffected share price from December 2016. The deal concludes a highly competitive bidding process (where Advent International was also a contender). The strategic rationale is to delist STADA to allow for a more aggressive long-term growth strategy, unburdened by quarterly public reporting.

STADA, which reported an EBITDA margin of in 2017, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Bad Vilbel, Germany, Stada is a leading European pharmaceutical manufacturer. Historically a generics player, the company has successfully transformed into a diversified "three-pillar" business: Consumer Healthcare (brands like Nizoral, Grippostad, Snup), Generics, and Specialty Pharmaceuticals (including Biosimilars).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2017

2016

Other operations with STADA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2025	CAPVEST PARTNERS	STADA	GERMANY	Generics / Labs

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 1b - 3b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of STADA by BAIN CAPITAL / CINVEN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: stada

Acquirer: cinven / bain capital